Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 4/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23145310 | 0.91 | KDM4E (0.41) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL25306767 | 0.84 | KDM4E (0.42) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL8217780 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL16984146 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL30327907 | 0.80 | DDB1 (0.44) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL23893026 | 0.80 | GPR119 (0.46) | GPR119KDM4ENAMPT | |
| SCHEMBL5894995 | 0.79 | DDB1 (0.44) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL20618024 | 0.79 | HPGD (0.46) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL2341857 | 0.78 | GPR119 (0.39) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL31088727 | 0.78 | USP2 (0.45) | USP2SMN1; SMN2GPR119KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250099481-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121713-A1 | BCL-2 INHIBITORS | NEW AVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021061823-A1 | CHEMICAL COMPOUNDS | Boragen, Inc. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | USP2 1244/4885SMN1; SMN2 2557/4885GPR119 1537/4885 |
| US-20250099481-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | USP2 1778/4885SMN1; SMN2 2544/4885GPR119 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.